Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

DYRK1A: A Promising Drug Target for Islet Transplant–Based Diabetes Therapies

  1. Bengt-Frederik Belgardt1 and
  2. Eckhard Lammert1,2⇑
  1. 1Institute for Beta Cell Biology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research, and German Center for Diabetes Research (DZD e.V.), Düsseldorf, Germany
  2. 2Institute for Metabolic Physiology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
  1. Corresponding author: Eckhard Lammert, lammert{at}hhu.de.
Diabetes 2016 Jun; 65(6): 1496-1498. https://doi.org/10.2337/dbi16-0013
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

A hallmark of all forms of diabetes, including type 2, is abnormal insulin release by pancreatic islets. This occurs either through impaired β-cell function and/or a reduction in β-cell number resulting from apoptosis or dedifferentiation (1). Currently available drugs only temporally ameliorate these processes, and many patients need insulin injections to reduce hyperglycemia 10–15 years after diagnosis (2). Mass transplantation of islets is not feasible due to the low availability of donor islets and side effects caused by immunosuppression. Further, although notable progress in targeted differentiation of stem cells into functional β-cells has been made (3), this approach has not yet advanced into routine clinical practice. An obvious therapeutic approach to improve islet transplantation would be to pharmacologically stimulate the proliferation of β-cells (Fig. 1) (4). These pharmacological agents could be used either to treat human islets before transplantation or to supplement protocols that transform stem cells into transplantable human islets. Alternatively, they could be used as oral medication to enhance β-cell proliferation once safety concerns are fully addressed.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Pancreatic islets are composed of different endocrine cells, in particular insulin-secreting β-cells (shown in pink). These cells secrete insulin into a dense microvascular network for distribution to peripheral tissues. Several structurally unrelated inhibitors of DYRK1A (e.g., 5-IT, harmine, and GNF4877) have been recently identified to promote NFATc-dependent β-cell proliferation in human pancreatic islets (8–10). Notably, these inhibitors promote cell cycle progression and expression of genes required for β-cell function. Green, factors stimulating β-cell proliferation; red, factors inhibiting β-cell proliferation.

β-Cell proliferation is rare in both adults who are healthy and adults who have diabetes, and the molecular underpinnings of the natural resistance of β-cells to undergo mitosis are complex (5), difficult to study (6), and species dependent (7). Nonetheless, several small molecules have been reported to induce human β-cell proliferation (8–10), among them the adenosine kinase inhibitor 5-iodotubercidin (5-IT) (11). The latter compound was previously identified to promote β-cell and δ-cell proliferation in murine (and porcine) islets (12).

In this issue of Diabetes, Dirice et al. (8) convincingly demonstrate that 5-IT also stimulates human β-cell proliferation in vitro, as well as upon transplantation of human islets into mice in vivo. Notably, the authors report that this effect appears to be specific to endocrine pancreatic cells, in particular the β-cells (Fig. 1), and they did not find any increase in cell proliferation in several nonpancreatic tissues (8). Of significance, long-term treatment of islets with 5-IT improved glucose-stimulated insulin secretion (8). The authors also present gene expression analyses showing that 5-IT enhanced expression of genes involved in proliferation (such as cyclins necessary for mitosis) and secretory function (such as glucose transporter 2) (8).

When the authors tested another adenosine kinase inhibitor, they surprisingly failed to observe increased proliferation rates (8). As most chemical compounds, especially kinase inhibitors, never exhibit exclusive specificity for only one target (13), the authors reasoned that 5-IT targets another enzyme to induce β-cell proliferation in the human setting. They consequently screened for kinases affected by 5-IT treatment and found that this treatment inhibited the dual-specificity tyrosine phosphorylation–regulated kinase DYRK1A and several other related kinases with high affinity (8). This is a crucial finding, as recent, independent reports demonstrated that the inhibition of DYRK1A by structurally unrelated compounds, including the plant-derived alkaloid harmine (9), switches on NFATc (nuclear factor of activated T-cells, cytoplasmic), a Ca2+-dependent transcription factor, in order to trigger human β-cell proliferation (8–10). The crucial role of NFATc in β-cell proliferation and insulin secretion has been previously established (14). Dirice et al. (8) went on to show that the effect of 5-IT on β-cell proliferation can be inhibited by concomitantly blocking NFATc activation.

Previous studies using genetically modified mice showed that partial ablation of DYRK1A inhibits β-cell growth and causes diabetes (15). In turn, genetic overexpression is beneficial in the context of diabetes (16). However, these findings are opposed to the effects observed when DYRK1A is pharmacologically inhibited (8–10). It is noteworthy that in genetic loss- and gain-of-function experiments (15,16), DYRK1A expression is apparently altered in all tissues from early embryonic development to adulthood. A distinctive role of DYRK1A in embryonic tissues (vs. adult) might thus explain these opposing results. Furthermore, gene deletion has full penetrance in the entire organism, whereas the compounds used to target DYRK1A might not reach all tissues relevant to glucose homeostasis. Finally, inconsistencies between mouse and human β-cell proliferation might further contribute to the contradictory results (7).

Multiple other kinases related to DYRK1A exist, which are also inhibited by 5-IT as described by Dirice et al. (8). It will be interesting to investigate if these related kinases are expressed at the protein level in β-cells and if they are involved in the observed mitogenic effects of 5-IT. Further, DYRK1A has been linked to numerous other biological functions, including neurological processes, especially in the context of Down syndrome (17). Of relevance, a recent report using conditional ablation of DYRK1A in mice showed that DYRK1A controls lymphocyte differentiation (18). For application as an antidiabetes drug, the compound requires further optimization followed by studies to comprehensively address drug safety. However, the current findings already warrant testing DYRK1A inhibitors in islet transplant–based diabetes therapies. For example, 5-IT could be applied in vitro to human islets to stimulate β-cell proliferation and improve functionality imminently after their transplantation. These inhibitors could also be added to increase β-cell density and functionality in islets derived from stem cells with the ultimate goal of improving the success of subsequent islet transplantations.

In conclusion, Dirice et al. (8) used advanced molecular tools to demonstrate that 5-IT inhibits DYRK1A with high affinity and induces β-cell proliferation in human islets in vitro and in vivo after transplantation. This study also prompts additional research on how DYRK1A activity is endogenously inhibited to facilitate β-cell proliferation (for example, during pregnancy and obesity) to help prevent diabetes.

Article Information

Acknowledgments. The authors thank Molly Kelly-Goss of the Peirce-Cottler Laboratory at the University of Virginia (Charlottesville, VA) for proofreading the manuscript and Yousun Koh, Koh Scientific Illustration, for the islet artwork.

Funding. The research of B.-F.B. and E.L. has been funded by the German Center for Diabetes Research (DZD e.V.), the Federal Ministry of Health, and the Ministry for Innovation, Science and Research of North Rhine-Westphalia.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 1660.

  • © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

  1. ↵
    1. Ashcroft FM,
    2. Rorsman P
    . Diabetes mellitus and the β cell: the last ten years. Cell 2012;148:1160–1171pmid:22424227
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Nathan DM
    . Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342–1349pmid:12397193
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Pagliuca FW,
    2. Millman JR,
    3. Gürtler M, et al
    . Generation of functional human pancreatic β cells in vitro. Cell 2014;159:428–439pmid:25303535
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Vetere A,
    2. Choudhary A,
    3. Burns SM,
    4. Wagner BK
    . Targeting the pancreatic β-cell to treat diabetes. Nat Rev Drug Discov 2014;13:278–289pmid:24525781
    OpenUrlCrossRefPubMed
  5. ↵
    1. Wang P,
    2. Fiaschi-Taesch NM,
    3. Vasavada RC,
    4. Scott DK,
    5. García-Ocaña A,
    6. Stewart AF
    . Diabetes mellitus--advances and challenges in human β-cell proliferation. Nat Rev Endocrinol 2015;11:201–212pmid:25687999
    OpenUrlPubMed
  6. ↵
    1. Taniguchi K,
    2. Russell MA,
    3. Richardson SJ,
    4. Morgan NG
    . The subcellular distribution of cyclin-D1 and cyclin-D3 within human islet cells varies according to the status of the pancreas donor. Diabetologia 2015;58:2056–2063pmid:26055066
    OpenUrlCrossRefPubMed
  7. ↵
    1. Avrahami D,
    2. Li C,
    3. Yu M, et al
    . Targeting the cell cycle inhibitor p57Kip2 promotes adult human β cell replication. J Clin Invest 2014;124:670–674pmid:24430183
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Dirice E,
    2. Walpita D,
    3. Vetere A, et al
    . Inhibition of DYRK1A stimulates human β-cell proliferation. Diabetes 2016;65:1660–1671pmid:26953159
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Wang P,
    2. Alvarez-Perez J-C,
    3. Felsenfeld DP, et al
    . A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat Med 2015;21:383–388pmid:25751815
    OpenUrlCrossRefPubMed
  10. ↵
    1. Shen W,
    2. Taylor B,
    3. Jin Q, et al
    . Inhibition of DYRK1A and GSK3B induces human β-cell proliferation. Nat Commun 2015;6:8372pmid:26496802
    OpenUrlCrossRefPubMed
  11. ↵
    1. Parkinson FE,
    2. Geiger JD
    . Effects of iodotubercidin on adenosine kinase activity and nucleoside transport in DDT1 MF-2 smooth muscle cells. J Pharmacol Exp Ther 1996;277:1397–1401pmid:8667202
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Annes JP,
    2. Ryu JH,
    3. Lam K, et al
    . Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication. Proc Natl Acad Sci U S A 2012;109:3915–3920pmid:22345561
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Bain J,
    2. Plater L,
    3. Elliott M, et al
    . The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297–315pmid:17850214
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Heit JJ,
    2. Apelqvist AA,
    3. Gu X, et al
    . Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006;443:345–349pmid:16988714
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Rachdi L,
    2. Kariyawasam D,
    3. Guez F, et al
    . Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass. Diabetologia 2014;57:960–969pmid:24477974
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Rachdi L,
    2. Kariyawasam D,
    3. Aïello V, et al
    . Dyrk1A induces pancreatic β cell mass expansion and improves glucose tolerance. Cell Cycle 2014;13:2221–2229pmid:24870561
    OpenUrlCrossRefPubMed
  17. ↵
    1. Wegiel J,
    2. Gong CX,
    3. Hwang YW
    . The role of DYRK1A in neurodegenerative diseases. FEBS J 2011;278:236–245pmid:21156028
    OpenUrlCrossRefPubMed
  18. ↵
    1. Thompson BJ,
    2. Bhansali R,
    3. Diebold L, et al
    . DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing cyclin D3. J Exp Med 2015;212:953–970pmid:26008897
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Diabetes: 65 (6)

In this Issue

June 2016, 65(6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
DYRK1A: A Promising Drug Target for Islet Transplant–Based Diabetes Therapies
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
DYRK1A: A Promising Drug Target for Islet Transplant–Based Diabetes Therapies
Bengt-Frederik Belgardt, Eckhard Lammert
Diabetes Jun 2016, 65 (6) 1496-1498; DOI: 10.2337/dbi16-0013

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

DYRK1A: A Promising Drug Target for Islet Transplant–Based Diabetes Therapies
Bengt-Frederik Belgardt, Eckhard Lammert
Diabetes Jun 2016, 65 (6) 1496-1498; DOI: 10.2337/dbi16-0013
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipose Tissue Malfunction Drives Metabolic Dysfunction in Alström Syndrome
  • Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.